Objective To investigate the value of combined detection of serum alpha- fetoprotein (AFP) and Golgi protein- 73 (GP73) in the diagnosis of hepatocellular carcinoma (HCC) and to provide a basis for early diagnosis and differential diagnosis of HCC. Methods A total of 408 patients hospitalized in Baoji Central Hospital from June 2012 to May 2013, as well as healthy persons who had normal test results in physical examination, were included in the study, and their specimens were collected. These patients were classified into HCC group (n =142) , chronic hepatitis group (n =156) , and liver cirrhosis group (n =110) . Serum levels of AFP and GP73 in the three groups were measured by electrochemiluminescence immunoassay and double- antibody sandwich enzyme- linked immunosorbent assay, respectively.Comparison of test results between groups was made by analysis of variance, and comparison of rates was made by chi- square test. The sensitivity and specificity of the two indicators for the diagnosis of HCC were calculated using MedCalc statistical software. Results The HCC group had significantly higher serum AFP and GP73 levels than the liver cirrhosis group and chronic hepatitis group ( P < 0. 05) ; the liver cirrhosis group had significantly higher serum AFP and GP73 levels than the chronic hepatitis group (P < 0. 05) . The sensitivity and specificity of the two indicators for the diagnosis of HCC were 95. 8% and 98. 6%, respectively, showing significant differences compared with those of each indicator alone (P < 0. 05) . Conclusion Combined detection of serum AFP and GP73 has high diagnostic value and clinical significance for HCC, and they can be used as indicators for early diagnosis and differential diagnosis of HCC.
肝细胞癌(hepatocellular carcinoma, HCC)是全球第六大常见肿瘤和我国第二大癌症死亡原因，早期发现、及时采取有效的治疗是改善患者生存预后的重要手段[1-2]。射频消融术(radiofrequency ablation，RFA)在早期肝癌特别是直径≤2 cm的患者中的疗效与手术切除相当，是不能切除的早期肝癌患者的首选治疗方法[3-6]。许多临床和实验研究[7-8]表明，全身炎症反应在肿瘤的进展中发挥重要作用。近年来，多项研究[9-11]证实了全身炎症标志物包括中性粒细胞/淋巴细胞比值(neutrophil-to-lymphocyte ratio, NLR)、红细胞分布宽度/淋巴细胞比值(red blood cell distribution width-to-lymphocyte ratio, RLR)、淋巴细胞/单核细胞比值(lymphocyte-to- monocyte ratio, LMR)等在包括HCC在内的恶性肿瘤和肝衰竭预后中的作用。本研究旨在探讨术前全身炎症标志物NLR、RLR及LMR在早期小肝癌RFA后预后中的价值。
选取2011年9月—2020年12月在天津市第二人民医院行RFA的132例初诊HCC患者。HCC的诊断及分期符合《原发性肝癌诊疗规范(2019年版)》[2]，基于动态增强MRI/CT、超声造影等2种或以上影像学支持，具体表现为动脉期病灶明显强化，门静脉期和/或平衡期病灶强化低于肝实质即“快进快出”的肝癌典型特征，伴或不伴AFP水平升高。纳入标准：(1)单个病灶直径≤3 cm；(2)巴塞罗那临床(BCLC)分期为0/A期；(3)不适合手术切除或者患者拒绝手术切除治疗；(4)接受RFA作为首次治疗。排除标准：(1)Child-Pugh分级为C级；(2)合并其他恶性肿瘤或严重心脑血管病等；(3)2周内服用过抗炎药物；(4)随访资料不全或围术期死亡；(5)随访时间＜3个月。
收集RFA前1周内的数据。一般资料：性别、年龄、BMI；病因学资料：HBV、HCV、代谢相关脂肪性肝病(MAFLD)和乙醇摄入等；实验室指标：血常规、肝功能、肾功能、AFP等；影像学资料：CT、磁共振成像(MRI)、腹部彩超、超声造影等。
在超声引导下经皮射频消融。严格按照《2011 CSLC/CSCO/CMA肝癌射频消融治疗规范的专家共识》流程进行。患者在穿刺部位接受2%盐酸利多卡因治疗，并静脉滴注50 mg盐酸哌替啶与50 mL 5%葡萄糖水混合。手术过程中持续监测心血管和呼吸系统。对于所有肿瘤，消融边缘至少应达到肿瘤边缘以外5 mm。完全消融定义为肝脏动态增强MRI/CT或超声造影提示肿瘤所在区域为低密度(超声表现为高回声)，动脉期无强化。术后28 d复查动态增强MRI/CT及动脉造影评估肿瘤是否完全消融。对于未完全消融者再次消融，直至肿瘤完全反应。
本研究的目标事件为无复发生存(recurrence free survival, RFS)和总生存(overall survival，OS)。RFS时间定义为从RFA术后到首次复发或死亡之间的时间。OS定义为从RFA术后到患者死亡或随访截止日期之间的时间。完全消融后，患者前2年内，每3个月复查1次AFP及动态增强MRI/CT、超声造影等，之后每半年监测1次上述指标，如动态增强MRI/CT和/或超声造影提示原病灶周围或者肝内远处出现动脉期异常强化影，门脉期及平衡期密度降低，伴或不伴AFP升高，考虑肿瘤复发，记录复发肿瘤的位置、数目、大小、有无血管侵犯等。通过多学科会诊综合评估患者情况，给予针对肝癌复发的相关治疗。治疗后继续随访，直至患者死亡或研究截止日期2021年6月30日。
采用SPSS 22.0软件及R语言4.0.3进行统计分析。计数资料组间比较采用χ2检验。运用X-tile工具以5年生存率及RFS率为结局事件，采用“枚举法”确定NLR、RLR和LMR的最佳截断值[12]。使用Kaplan-Meier方法绘制生存曲线，并采用log-rank检验比较复发及生存的组间差异。单因素分析采用log-rank检验，将log-rank检验分析中具有统计学意义的因素纳入多因素Cox回归分析以确定RFS率与OS率的危险因素，计算风险比(HR)及其95%CI。P＜0.05为差异有统计学意义。
132例患者中男性96例，平均年龄(58.50±9.66)岁。利用患者数据对5年OS和RFS进行X-tile分析，确定NLR、RLR和LMR的最佳截断值分别为4.1、18.3和6(图 1~3)。根据NLR、RLR、LMR分组与OS及RFS的相关性，将NLR、RLR及LMR按积分计算(表 1)，根据N-R-L评分的得分情况将患者分为3组：N-R-L 0分组，N-R-L 1分组和N-R-L 2分组，并将其作为OS和RFS的预后指标。3组患者Child-Pugh分级、Alb比较差异均有统计学意义(P值均＜0.05)(表 2)。
| 变量 | 得分 |
| NLR | |
| ＜4.1 | 0 |
| ≥4.1 | 1 |
| RLR | |
| ＜18.3 | 0 |
| ≥18.3 | 1 |
| LMR | |
| ＜6 | 0 |
| ≥6 | 1 |
| N-R-L | |
| NLR+RLR+LMR=0 | 0 |
| NLR+RLR+LMR=1 | 1 |
| NLR+RLR+LMR=2 | 2 |
| 注：N-R-L，NLR、RLR和LMR三项评分之和。 | |
| 临床特征 | N-R-L 0分组(n=92) | N-R-L 1分组(n=29) | N-R-L 2分组(n=11) | χ2值 | P值 |
| 性别[例(%)] | 0.545 | 0.762 | |||
| 男 | 66(71.7) | 21(72.4) | 9(81.8) | ||
| 女 | 26(28.3) | 8(27.6) | 2(18.2) | ||
| 年龄[例(%)] | 0.371 | 0.831 | |||
| ＜60岁 | 48(52.2) | 17(58.6) | 6(54.5) | ||
| ≥ 60岁 | 44(47.8) | 12(41.4) | 5(45.5) | ||
| BMI[例(%)] | 2.024 | 0.363 | |||
| ＜24 kg/m2 | 42(45.7) | 9(31.0) | 5(45.5) | ||
| ≥24 kg/m2 | 50(54.3) | 20(69.0) | 6(54.5) | ||
| Child-Pugh分级[例(%)] | 10.992 | 0.001 | |||
| A级 | 81(88.0) | 26(89.7) | 4(36.4) | ||
| B级 | 11(12.0) | 3(10.3) | 7(63.6) | ||
| BCLC分期[例(%)] | 3.640 | 0.056 | |||
| 0期 | 18(19.6) | 3(10.3) | 0 | ||
| A期 | 74(80.4) | 26(89.7) | 11(100) | ||
| 肿瘤直径[例(%)] | 3.876 | 0.144 | |||
| ＜2 cm | 53(57.6) | 17(58.6) | 3(27.3) | ||
| ≥2 cm | 39(42.4) | 12(41.4) | 8(72.7) | ||
| HBV感染[例(%)] | 1.601 | 0.449 | |||
| 否 | 22(23.9) | 5(17.2) | 4(36.4) | ||
| 是 | 70(76.1) | 24(82.8) | 7(63.6) | ||
| HCV感染[例(%)] | 1.029 | 0.598 | |||
| 否 | 76(82.6) | 22(75.9) | 8(71.7) | ||
| 是 | 16(17.4) | 7(24.1) | 3(27.3) | ||
| MAFLD[例(%)] | 0.367 | 0.832 | |||
| 否 | 56(60.9) | 16(55.2) | 7(63.6) | ||
| 是 | 36(39.1) | 13(44.8) | 4(36.4) | ||
| AFP[例(%)] | 1.266 | 0.531 | |||
| ＜15 ng/mL | 59(64.1) | 21(72.4) | 6(54.5) | ||
| ≥15 ng/mL | 33(35.9) | 8(27.6) | 5(45.5) | ||
| ALBI分级[例(%)] | 2.845 | 0.092 | |||
| 1级 | 54(58.7) | 16(55.2) | 5(45.4) | ||
| 2级 | 36(39.1) | 13(44.8) | 3(27.3) | ||
| 3级 | 2(2.2) | 0 | 3(27.3) | ||
| TBil[例(%)] | 0.904 | 0.636 | |||
| ≤20 μmol/L | 55(59.8) | 16(55.2) | 5(45.5) | ||
| ＞20 μmol/L | 37(40.2) | 13(44.8) | 6(54.5) | ||
| Alb[例(%)] | 5.699 | 0.017 | |||
| ≥35 g/L | 82(89.1) | 23(79.3) | 7(63.6) | ||
| ＜35 g/L | 10(10.9) | 6(20.7) | 4(36.4) | ||
| ALT[例(%)] | 0.109 | 0.741 | |||
| ≤50 U/L | 76(82.6) | 28(96.6) | 7(63.6) | ||
| ＞50 U/L | 16(17.4) | 1(3.4) | 4(36.4) | ||
| AST[例(%)] | 1.572 | 0.456 | |||
| ≤40 U/L | 71(77.2) | 24(82.8) | 7(63.6) | ||
| ＞40 U/L | 21(22.8) | 5(17.2) | 4(36.4) | ||
| MELD评分[例(%)] | 3.022 | 0.221 | |||
| ＜9分 | 65(70.7) | 18(62.1) | 5(45.5) | ||
| ≥9分 | 27(29.3) | 11(37.9) | 6(54.5) | ||
| 注：ALBI分级，白蛋白-胆红素分级。 | |||||
中位随访时间为34个月(5~111个月)。所有患者的1、3和5年RFS率分别为64.3%、40.0%和21.5%，中位RFS为26个月；1、3和5年OS率分别为97.6%、82.1%和69.8%。N-R-L 0分组、N-R-L 1分组和N-R-L 2分组的1、3和5年RFS率分别为76.9%、52.5%、33.3%，42.9%、13.1%、0和11.1%、0、0(χ2=35.345，P＜0.000 1)(图 4)；3组的1、3和5年OS率分别为100%、96.3%、90.7%，96.6%、60.4%、41.3%和81.8%、46.8%、15.6%(χ2=38.460，P＜0.000 1)(图 4)。N-R-L 0分组、N-R-L 1分组和N-R-L 2分组的中位RFS分别为38个月、10个月和5个月，组间差异有统计学意义(χ2=35.345，P＜0.000 1)。
对患者RFA术前相关指标进行单因素及多因素分析，以确定RFS率的预测因素(表 3)。log-rank检验结果显示，男性、Child-Pugh B级、肿瘤直径≥2 cm、TBil＞20 μmol/L、Alb＞35 g/L、ALBI分级2/3级以及N-R-L评分1/2分与RFS率显著相关(P值均＜0.05)。进一步行多因素Cox回归分析结果表明，肿瘤直径≥2 cm(HR=2.10, 95%CI: 1.28~3.43，P=0.003)、N-R-L评分1分(HR= 3.14, 95%CI: 1.81~5.46，P＜0.000 1)以及N-R-L评分2分(HR=2.61, 95%CI: 1.06~6.42，P=0.037)是RFS率的独立预测因素(P值均＜0.05)。
| 变量 | 单因素分析 | 多因素分析 | |||
| HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 性别(男/女) | 1.97(1.14~3.40) | 0.015 | 1.55(0.87~2.76) | 0.136 | |
| BMI(≥24 kg/m2/＜24 kg/m2) | 1.22(0.77~1.92) | 0.402 | |||
| MAFLD(是/否) | 1.03(0.65~1.61) | 0.916 | |||
| Child-Pugh分级(B级/A级) | 2.58(1.50~4.45) | 0.001 | 1.28(0.56~2.91) | 0.564 | |
| 肿瘤直径(≥2 cm/＜2 cm) | 2.28(1.43~3.62) | 0.001 | 2.10(1.28~3.43) | 0.003 | |
| BCLC分期(A期/0期) | 2.06(0.89~4.75) | 0.090 | |||
| ALT(＞50 U/L/≤50 U/L) | 1.41(0.78~2.57) | 0.260 | |||
| AST(＞40 U/L/≤40 U/L) | 1.63(0.98~2.70) | 0.058 | |||
| TBil(≤20 μmol/L/＞20 μmol/L) | 1.69(1.07~2.65) | 0.024 | 1.60(0.96~2.67) | 0.074 | |
| Alb(＜35 g/L/≥35 g/L) | 2.45(1.45~4.12) | 0.001 | 1.01(0.44~2.32) | 0.974 | |
| AFP(＞400 ng/mL/≤400 ng/mL) | 0.81(0.33~2.01) | 0.650 | |||
| ALBI分级(ref: 1级) | |||||
| 2级 | 1.25(0.79~2.00) | 0.341 | 0.92(0.49~1.70) | 0.781 | |
| 3级 | 4.15(1.61~10.70) | 0.003 | 1.91(0.48~7.59) | 0.356 | |
| MELD评分(＞9分/≤9分) | 1.44(0.91~2.28) | 0.124 | |||
| N-R-L得分(ref: 0分) | |||||
| 1分 | 3.13(1.89~5.20) | ＜0.000 1 | 3.14(1.81~5.46) | ＜0.000 1 | |
| 2分 | 4.99(2.40~10.37) | ＜0.000 1 | 2.61(1.06~6.42) | 0.037 | |
表 4总结了RFA术后OS率的预测因素。log-rank检验结果提示Child-Pugh B级、肿瘤直径≥2 cm、TBil＞20 μmol/L、Alb＞35 g/L、ALBI分级2/3级以及N-R-L评分1/2分与OS显著相关。多因素Cox回归结果表明，肿瘤直径≥2 cm(HR=3.67, 95%CI: 1.58 ~ 8.52，P=0.002)、N-R-L评分1分(HR=8.27, 95%CI: 3.15 ~ 21.71，P＜0.000 1)以及N-R-L评分2分(HR=14.59, 95%CI: 3.96 ~ 53.78，P＜0.000 1)是OS率的独立预测因素。
| 变量 | 单因素分析 | 多因素分析 | |||
| HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 性别(男/女) | 2.17(0.88~5.33) | 0.093 | |||
| BMI(≥24 kg/m2/＜24 kg/m2) | 1.64(0.78~3.44) | 0.191 | |||
| MAFLD(是/否) | 1.20(0.58~2.51) | 0.620 | |||
| Child-Pugh分级(B级/A级) | 3.54(1.52~8.25) | 0.003 | 0.99(0.28~3.52) | 0.987 | |
| 肿瘤直径(≥2 cm/＜2 cm) | 2.89(1.36~6.14) | 0.006 | 3.67(1.58~8.52) | 0.002 | |
| BCLC分期(A期/0期) | 1.10(0.33~3.63) | 0.880 | |||
| ALT(＞50 U/L/≤50 U/L) | 1.21(0.46~3.17) | 0.705 | |||
| AST(＞40 U/L/≤40 U/L) | 1.30(0.58~2.94) | 0.530 | |||
| TBil(≤20 μmol/L/＞20 μmol/L) | 2.27(1.08~4.76) | 0.030 | 1.97(0.82~4.77) | 0.132 | |
| Alb(＜35 g/L/≥35 g/L) | 3.49(1.58~7.74) | 0.002 | 1.36(0.36~5.09) | 0.649 | |
| AFP(＞400 ng/mL/≤400 ng/mL) | 1.35(0.41~4.50) | 0.621 | |||
| ALBI分级(ref: 1级) | |||||
| 2级 | 1.67(0.78~3.56) | 0.184 | 0.97(0.35~2.65) | 0.950 | |
| 3级 | 12.94(2.55~65.68) | 0.002 | 2.11(0.25~17.94) | 0.495 | |
| MELD评分(＞9分/≤9分) | 1.59(0.75~3.33) | 0.224 | |||
| N-R-L得分(ref: 0分) | |||||
| 1分 | 6.92(2.82~17.00) | ＜0.000 1 | 8.27(3.15~21.71) | ＜0.000 1 | |
| 2分 | 13.50(4.68~38.91) | ＜0.000 1 | 14.59(3.96~53.78) | ＜0.000 1 | |
多项研究表明，对于不可切除的早期小肝癌，RFA能提供良好的治疗效果。本研究选取了单发直径≤3 cm的早期/极早期HCC患者，将RFA作为首次治疗方法。在整个随访期内，共有77例(58.3%)复发，29例(22%)死亡，与先前研究[4, 13-14]结果类似。所有患者接受RFA治疗后，仅3例患者出现轻微并发症，经治疗后均好转，没有患者出现严重并发症，表明RFA安全性较高，更具成本效益。
评估了RFA率与OS率的危险因素，发现肿瘤直径≥2 cm、N-R-L评分1分及2分与患者不良预后独立相关。HCC的复发及预后的差异与初始肿瘤大小相关已经在先前的研究[15-16]中被证实。在HCC的发生发展中，随着病灶直径的增加，微浸润的发生率明显增加，这可能是HCC治疗后复发的重要原因。研究[4]表明，对于直径≤3 cm的HCC患者，HCC≥2 cm的微转移和微血管浸润更明显。另外，肿瘤直径增大可能造成消融不彻底，残存的微病灶直接导致复发，这些结果均会影响患者的生存预后。
炎症在肿瘤发生发展的各个阶段均发挥重要作用，可驱动肿瘤的发生、生长、进展和转移等重要过程[17-18]。除了局部肿瘤微环境外，全身性炎症反应通过干扰组织内环境稳态从而影响肿瘤的发展，特别是肿瘤的转移[19]。血常规作为反映全身炎症反应最普遍的工具，在临床广泛应用且易于获取。单独的血细胞计数可能与整体预后没有显著关系，但由这些细胞计数组合产生的全身炎症标志物如NLR、RLR和LMR等被认为是各类癌症的独立预测因素。
淋巴细胞是机体免疫监视和免疫应答的重要组成成分，参与肿瘤的免疫反应，特别是在抗肿瘤增殖和转移的过程[20]。淋巴细胞浸润增加与癌症患者预后良好相关[21]，而淋巴细胞数量减少和功能抑制可能会削弱肿瘤特异性免疫，造成利于肿瘤侵袭和转移的环境，进而影响患者预后[22-23]。中性粒细胞可直接释放炎症因子，促进肿瘤血管生成，加速肿瘤的生长和转移[24]。NLR是反映中性粒细胞促肿瘤特性与淋巴细胞抗肿瘤宿主免疫反应之间平衡的一个因素，但在炎症环境下，随着中性粒细胞增加和淋巴细胞减少，这一平衡被打破，直接导致机体抗肿瘤能力下降。这提示机体处于抗肿瘤免疫抑制状态，炎症反应将向促肿瘤进展方向发展，最终导致患者预后不良。另外，炎症可以刺激单核细胞到外周血，进而被招募到肿瘤组织并分化为肿瘤相关巨噬细胞，进一步与肿瘤细胞相互作用促进肿瘤进展[25-26]。红细胞分布宽度(red blood cell distribution width, RDW)反映了红细胞在循环中体积分布的变化。有研究[27]表明RDW升高与HCC患者无病生存率较低和OS率较差相关。而作为RDW与淋巴细胞比值, RLR升高已被证明能够预测肝功能衰竭和结肠癌的不良预后，并与肝硬化的严重程度相关[9-10, 28]。
与先前结果一致，本研究亦明确了NLR、RLR和LMR在早期小肝癌RFA后的预后价值。由于先前研究对于上述炎症标志物的分组尚无统一标准，本研究采用X-tile工具基于患者5年OS及RFS计算出3个指标的最佳截断值分别为4.1、18.3和6，据此分组后三者在患者RFS及OS方面均表现出优异的预后价值，特别是将三者结合后得到的N-R-L评分，在N-R-L评分≥1与早期HCC首次RFA后的早期复发和预后不良显著相关，因此可作为早期HCC患者RFA治疗预后不良的独立预后生物标志物。
另外，本研究的大多数患者为HBV或HCV相关HCC，机体本身存在慢性持续性炎症。肿瘤相关炎症反应刺激炎症介质的释放，加之血细胞计数异常所致的抗肿瘤免疫功能下降，为肿瘤的侵袭和转移提供有利条件。提示炎症反应越明显，N-R-L评分越高，患者预后也越差。
总之，全身炎症反应标志物N-R-L评分作为一种简单、易于获取且成本极低的指标，有望成为有用的无创生物标志物，用以预测早期HCC患者RFA术后的复发和生存。
|
[1]MARRERO JA, EI-SERAG HB.Alpha-fetoprotein should be included in the hepatocellulor carcinoma surveillance guidelines of the American Association for the Study of Liver Diaeases[J].Hepatology, 2011, 53 (3) :1060.
|
|
[2]LIU ZY, CHEN ZG.Diagnostic evaluation of AFP、AFU、Fer、GP73in primary hepatocellular carcinoma[J].J Henan Med Coll Staff Workers, 2011, 23 (6) :654-656. (in Chinese) 刘志云, 陈志刚.AFP、AFU、Fer、GP73联合检测在原发性肝癌诊断中的价值[J].河南职工医学院学报, 2011, 23 (6) :654-656.
|
|
[3]Chinese Society of Liver Cancer.Clinical diagnosis and staging criteria for primary liver cancer[J].Chin J Hepatol, 2001, 9 (6) :324. (in Chinese) 中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.
|
|
[4]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病分会和肝病学分会.病毒性肝炎的防治方案[J].传染病信息, 2001, 19 (1) :56-62.
|
|
[5]LIN TJ.Serum AFP measurement and its clinical significance in patients with chronic viral hepatitis[J].China Med Herald, 2008, 5 (16) :97-98. (in Chinese) 林铁军.慢性病毒性肝炎患者血清中甲胎蛋白的检测及临床意义[J].中国医药导报, 2008, 5 (16) :97-98.
|
|
[6]LYU XH.Significance of Golgi protein-73 in diagnosis of liver cancer[J].Chin Hepatol, 2012, 17 (2) :104-105. (in Chinese) 吕新华.高尔基体蛋白73在肝癌诊断中的意义[J].肝脏, 2012, 17 (2) :104-105.
|
|
[7]ZHANG WP.Alpha-fetoprotein and liver cancer:a new understanding of an old problem[J].J Med Res, 2013, 42 (6) :3-5. (in Chinese) 章卫平.甲胎蛋白与肝癌:老问题的新认识[J].医学研究杂志, 2013, 42 (6) :3-5.
|
|
[8]ZHAO CH, ZHOU WF, CHEN WH, et al.Clinical significance ofα-fetoprotein in initial diagnosis of primary hepatic cancer[J].J Clin Hepatol, 2013, 29 (9) :698-701. (in Chinese) 赵春华, 周文峰, 陈维华, 等.甲胎蛋白在原发性肝癌首诊中的价值[J].临床肝胆病杂志, 2013, 29 (9) :698-701.
|
|
[9]LUO WM, CHEN L, CAO YL, et al.Diagnostic significance of combined application of serum GP73 and AFP-L3 in patients with PHC[J].J Clin Exp Med, 2013, 12 (13) :1005-1006. (in Chinese) 罗文明, 陈琳, 曹亚丽, 等.血清GP73及AFP-L3检测在原发性肝癌诊断中的意义[J].临床和实验医学杂志, 2013, 12 (13) :1005-1006.
|
|
[10]KLADNEY RD, CUI X, BULLA GA, et al.Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease[J].Hepatology, 2002, 35 (6) :1431-1440.
|
|
[11]YAO XN, WANG QM.GP73 and hepatocellular carcinoma diagnosis[J].Chem Life, 2010, 30 (3) :480-483. (in Chinese) 姚西宁, 王清明.高尔基体蛋白73与肝癌诊断[J].生命的化学, 2010, 30 (3) :480-483.
|
|
[12]BLOCK TM, COMUNALE MA, LOW MAN M, et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J].Proc Natl Acad Sci U S A, 2005, 102 (3) :779-784.
|
|
[13]CASSANDRA W.Researchers look for sweet method to diagnose cancer[J].Nature Medicine, 2007, 13 (11) :1267.
|
|
[14]OZKAN H, ERDAL H, TUTKAK H, et al.Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J].Digestion, 2011, 83 (1-2) :83-88.
|
|
[15]YANG SP, LI HY.Diagnostic value of combined measurement of serum AFP and Golgi protein-73 for primary liver cancer[J].Chongqing Med J, 2012, 41 (27) :2880-2882. (in Chinese) 杨收平, 李海英.血清AFP和高尔基体蛋白73联合检测对原发性肝癌的诊断价值[J].重庆医学, 2012, 41 (27) :2880-2882.
|
| [1] | Yuanzhi HUANG, Fuchuan WANG, Yi DONG, Zhiqiang XU, Yinjie GAO, Jianguo YAN, Lili CAO, Danni FENG, Min ZHANG. Liver disease phenotypes and clinical features of patients with different genotypes of Wilson’s disease[J]. Journal of Clinical Hepatology, 2024, 40(8): 1627-1632. doi: 10.12449/JCH240819 |
| [2] | Rui HAN, Liaoyun ZHANG. Clinical epidemiology and pathological features of cryptogenic cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1650-1653. doi: 10.3969/j.issn.1001-5256.2022.07.036 |
| [3] | Jinni HUANG, Jianning JIANG, Dandan LIANG, Shiyu LONG, Guozhen DONG, Man SU, Jijiao LI, Chunling TENG, Ping ZHANG, Minghua SU. Epidemiological features and antiviral response of genotype 6 chronic hepatitis C[J]. Journal of Clinical Hepatology, 2022, 38(4): 793-797. doi: 10.3969/j.issn.1001-5256.2022.04.011 |
| [4] | Chaomei QIN, Yongming LIU, Heling SU. Association of hepatitis B and hepatitis C with type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2021, 37(4): 921-924. doi: 10.3969/j.issn.1001-5256.2021.04.042 |
| [5] | Shan SHAN, Lianhui ZHAO, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA. Definition, etiology, and epidemiology of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 14-16. doi: 10.3969/j.issn.1001-5256.2021.01.003 |
| [6] | Li Jing, Wang YuFang. Epidemiological features of inflammatory bowel disease with hepatobiliary and pancreatic diseases[J]. Journal of Clinical Hepatology, 2020, 36(7): 1461-1466. doi: 10.3969/j.issn.1001-5256.2020.07.005 |
| [7] | Shu YunRan, Li JunQi, Liu Qiong. Epidemiology of nonalcoholic fatty liver disease and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2085-2090. doi: 10.3969/j.issn.1001-5256.2019.09.045 |
| [8] | Hu JiangFeng, Lu LunGen. Research advances in the epidemiological features, pathogenesis, and diagnosis and treatment of alcoholic pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(2): 448-450. doi: 10.3969/j.issn.1001-5256.2019.02.047 |
| [9] | Shen Tao, Huang Xin, Wang YuYa, Zhuang Hui. Current status of epidemiological studies on drug-induced liver injury in China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1152-1155. doi: 10.3969/j.issn.1001-5256.2018.06.002 |
| [10] | Li Jie. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. Journal of Clinical Hepatology, 2018, 34(12): 2515-2519. doi: 10.3969/j.issn.1001-5256.2018.12.006 |
| [11] | Ding YuPing, Li Hai, Zhang Wen, Xia ShiHai, Bi Xun. Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J]. Journal of Clinical Hepatology, 2017, 33(12): 2355-2360. doi: 10.3969/j.issn.1001-5256.2017.12.020 |
| [12] | Ding ShiMei, Qu Wei, Liang Xi, Jiao Yang, Zhang Jing, Jia XiaoLi, Wang WenJun, Dang ShuangSuo. Relationship between chronic hepatitis C virus genotype and thyroid function[J]. Journal of Clinical Hepatology, 2015, 31(8): 1271-1274. doi: 10.3969/j.issn.1001-5256.2015.08.021 |
| [13] | Wang LiFeng, Li YuanYuan, Jin Lei, Wang FuSheng. Epidemiology and natural history of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 165-170. doi: 10.3969/j.issn.1001-5256.2015.02.005 |
| [14] | Zheng DongChun, Nie YuanXia, Liang HaiLin, Hu YueLin, Cheng Xiao, Feng XiaoXia, Chen YongPing. Epidemiological features and serological changes in sporadic acute hepatitis B among adults: an analysis of 202 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 30-33. doi: 10.3969/j.issn.1001-5256.2014.01.009 |
| [15] | Jiang ShuiQing, Wang Jian, Hu XiaoBin, Li YuZhi, Lu YouJie, Tong Rui, Tong Min. Epidemiology and treatment strategies for hepatitis C in the northern region of Anhui province[J]. Journal of Clinical Hepatology, 2012, 28(12): 937-940. |
| [16] | Cheng Ling, Hong GuoHu, Guo Yan, Mao Qing. Prediction of HLA-DRB1*0311/0401 in recognizing epitopes of HCV Core protein of different genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 61-64. |
| [17] | Zhang WenJie, Liu LiJun, Du ShaoCai, Li ChaoXia, Lu QingYun, Yang ShaoHua. The prevalence of hepatitis C virus genotype in Lanzhou area[J]. Journal of Clinical Hepatology, 2010, 26(3): 290-291+294. |
| [19] | Chen Yan, Tian DeYing, Xia NingShao. Epidemiology and the genotypes of HEV isolated from patients with hepatitis E in Wuhan[J]. Journal of Clinical Hepatology, 2006, 22(1): 36-38. |
| [20] | Li TingMing, Zhu YouFu, He HaiTang, Mao QianGuo, Wu AiHua, Liang YuFang, Luo KangXian. The relation between chinese hepatitis B virus genotype B C and efficacy of interferon-α.[J]. Journal of Clinical Hepatology, 2005, 21(1): 16-18. |
| 1. | 陈玉凤，明文，陈镜晶，王茜，李溢馨. FAR、RLR水平对乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者治疗后再出血风险的评估价值. 现代生物医学进展. 2025(01): 72-79 .  | |
| 2. | 赵孟杰，邢恩涛，董源，金鹏飞，孙景武. 不可逆电穿孔和射频消融治疗原发性肝癌效果比较. 青岛大学学报(医学版). 2024(01): 110-114 . | |
| 3. | 谢亚明，梁磊，肖遵强，刘军伟，张成武，黄东胜. Naples预后评分对肝细胞癌患者肝切除术后预后的影响. 中华肝胆外科杂志. 2024(05): 341-346 . | |
| 4. | 叶建刚，彭俊文，李莉. 乳腺X线和MRI参数联合外周血RLR水平预测乳腺癌改良根治术后复发转移的价值. 中华内分泌外科杂志. 2024(03): 404-408 . | |
| 5. | 张玉霞，谢钦，魏思瑞，姜龙琳，谢丽，韩泳涛，缪艳. 炎症及营养指标对老年食管鳞癌患者术后生存的预测价值. 中华消化外科杂志. 2024(09): 1200-1208 . | |
| 6. | 张兰，李胜棉. 《肝癌新辅助治疗中国专家共识(2023版)》专家解读. 疑难病杂志. 2024(11): 1281-1286 . | |
| 7. | 潘伟华，黄腾钦，曾耿华. 经皮微波消融术和腹腔镜肝癌切除术治疗小肝癌的临床效果. 中国医学创新. 2023(17): 17-20 . | |
| 8. | 张旭，哈福双，李凤惠，高艳颖，梁静. 肝纤维化-4指数（FIB-4）联合预后营养指数（PNI）对早期肝癌射频消融术后复发及生存期的预测价值. 临床肝胆病杂志. 2023(11): 2614-2622 .  本站查看 | |
| 9. | 陈雪岩，乔建梁，李军，牛剑祥，赵建国，韩赛，孟兴凯. 小野寺预后营养指数对消化系统恶性肿瘤预后预测价值的研究进展. 中华消化外科杂志. 2022(10): 1390-1394 . |
The first journal specializing in hepatobiliary and pancreatic diseases in China
Supervisor：Ministry of Education of the People's Republic of China
Sponsor：Jilin University
Academic Support: Chinese Society of Hepatology，Chinese Medical Association
Address: 461 Xinjiang Road, Changchun
Submit：0431-88782044
Peer review：0431-88783542
Email：lcgdb@vip.163.com
Website Design © 2020 Editorial Board of Journal of Clinical Hepatology
吉ICP备10000617号-1
Supported by: Beijing Renhe Information Technology Co. Ltd
CHU WK, WU X, ZHANG P, et al. Value of inflammatory biomarkers in predicting the prognosis of early small hepatocellular carcinoma after radiofrequency ablation[J]. J Clin Hepatol, 2022, 38(4): 843-850. DOI: 10.3969/j.issn.1001-5256.2022.04.020.
| 变量 | 得分 |
| NLR | |
| ＜4.1 | 0 |
| ≥4.1 | 1 |
| RLR | |
| ＜18.3 | 0 |
| ≥18.3 | 1 |
| LMR | |
| ＜6 | 0 |
| ≥6 | 1 |
| N-R-L | |
| NLR+RLR+LMR=0 | 0 |
| NLR+RLR+LMR=1 | 1 |
| NLR+RLR+LMR=2 | 2 |
| 注：N-R-L，NLR、RLR和LMR三项评分之和。 | |
| 临床特征 | N-R-L 0分组(n=92) | N-R-L 1分组(n=29) | N-R-L 2分组(n=11) | χ2值 | P值 |
| 性别[例(%)] | 0.545 | 0.762 | |||
| 男 | 66(71.7) | 21(72.4) | 9(81.8) | ||
| 女 | 26(28.3) | 8(27.6) | 2(18.2) | ||
| 年龄[例(%)] | 0.371 | 0.831 | |||
| ＜60岁 | 48(52.2) | 17(58.6) | 6(54.5) | ||
| ≥ 60岁 | 44(47.8) | 12(41.4) | 5(45.5) | ||
| BMI[例(%)] | 2.024 | 0.363 | |||
| ＜24 kg/m2 | 42(45.7) | 9(31.0) | 5(45.5) | ||
| ≥24 kg/m2 | 50(54.3) | 20(69.0) | 6(54.5) | ||
| Child-Pugh分级[例(%)] | 10.992 | 0.001 | |||
| A级 | 81(88.0) | 26(89.7) | 4(36.4) | ||
| B级 | 11(12.0) | 3(10.3) | 7(63.6) | ||
| BCLC分期[例(%)] | 3.640 | 0.056 | |||
| 0期 | 18(19.6) | 3(10.3) | 0 | ||
| A期 | 74(80.4) | 26(89.7) | 11(100) | ||
| 肿瘤直径[例(%)] | 3.876 | 0.144 | |||
| ＜2 cm | 53(57.6) | 17(58.6) | 3(27.3) | ||
| ≥2 cm | 39(42.4) | 12(41.4) | 8(72.7) | ||
| HBV感染[例(%)] | 1.601 | 0.449 | |||
| 否 | 22(23.9) | 5(17.2) | 4(36.4) | ||
| 是 | 70(76.1) | 24(82.8) | 7(63.6) | ||
| HCV感染[例(%)] | 1.029 | 0.598 | |||
| 否 | 76(82.6) | 22(75.9) | 8(71.7) | ||
| 是 | 16(17.4) | 7(24.1) | 3(27.3) | ||
| MAFLD[例(%)] | 0.367 | 0.832 | |||
| 否 | 56(60.9) | 16(55.2) | 7(63.6) | ||
| 是 | 36(39.1) | 13(44.8) | 4(36.4) | ||
| AFP[例(%)] | 1.266 | 0.531 | |||
| ＜15 ng/mL | 59(64.1) | 21(72.4) | 6(54.5) | ||
| ≥15 ng/mL | 33(35.9) | 8(27.6) | 5(45.5) | ||
| ALBI分级[例(%)] | 2.845 | 0.092 | |||
| 1级 | 54(58.7) | 16(55.2) | 5(45.4) | ||
| 2级 | 36(39.1) | 13(44.8) | 3(27.3) | ||
| 3级 | 2(2.2) | 0 | 3(27.3) | ||
| TBil[例(%)] | 0.904 | 0.636 | |||
| ≤20 μmol/L | 55(59.8) | 16(55.2) | 5(45.5) | ||
| ＞20 μmol/L | 37(40.2) | 13(44.8) | 6(54.5) | ||
| Alb[例(%)] | 5.699 | 0.017 | |||
| ≥35 g/L | 82(89.1) | 23(79.3) | 7(63.6) | ||
| ＜35 g/L | 10(10.9) | 6(20.7) | 4(36.4) | ||
| ALT[例(%)] | 0.109 | 0.741 | |||
| ≤50 U/L | 76(82.6) | 28(96.6) | 7(63.6) | ||
| ＞50 U/L | 16(17.4) | 1(3.4) | 4(36.4) | ||
| AST[例(%)] | 1.572 | 0.456 | |||
| ≤40 U/L | 71(77.2) | 24(82.8) | 7(63.6) | ||
| ＞40 U/L | 21(22.8) | 5(17.2) | 4(36.4) | ||
| MELD评分[例(%)] | 3.022 | 0.221 | |||
| ＜9分 | 65(70.7) | 18(62.1) | 5(45.5) | ||
| ≥9分 | 27(29.3) | 11(37.9) | 6(54.5) | ||
| 注：ALBI分级，白蛋白-胆红素分级。 | |||||
| 变量 | 单因素分析 | 多因素分析 | |||
| HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 性别(男/女) | 1.97(1.14~3.40) | 0.015 | 1.55(0.87~2.76) | 0.136 | |
| BMI(≥24 kg/m2/＜24 kg/m2) | 1.22(0.77~1.92) | 0.402 | |||
| MAFLD(是/否) | 1.03(0.65~1.61) | 0.916 | |||
| Child-Pugh分级(B级/A级) | 2.58(1.50~4.45) | 0.001 | 1.28(0.56~2.91) | 0.564 | |
| 肿瘤直径(≥2 cm/＜2 cm) | 2.28(1.43~3.62) | 0.001 | 2.10(1.28~3.43) | 0.003 | |
| BCLC分期(A期/0期) | 2.06(0.89~4.75) | 0.090 | |||
| ALT(＞50 U/L/≤50 U/L) | 1.41(0.78~2.57) | 0.260 | |||
| AST(＞40 U/L/≤40 U/L) | 1.63(0.98~2.70) | 0.058 | |||
| TBil(≤20 μmol/L/＞20 μmol/L) | 1.69(1.07~2.65) | 0.024 | 1.60(0.96~2.67) | 0.074 | |
| Alb(＜35 g/L/≥35 g/L) | 2.45(1.45~4.12) | 0.001 | 1.01(0.44~2.32) | 0.974 | |
| AFP(＞400 ng/mL/≤400 ng/mL) | 0.81(0.33~2.01) | 0.650 | |||
| ALBI分级(ref: 1级) | |||||
| 2级 | 1.25(0.79~2.00) | 0.341 | 0.92(0.49~1.70) | 0.781 | |
| 3级 | 4.15(1.61~10.70) | 0.003 | 1.91(0.48~7.59) | 0.356 | |
| MELD评分(＞9分/≤9分) | 1.44(0.91~2.28) | 0.124 | |||
| N-R-L得分(ref: 0分) | |||||
| 1分 | 3.13(1.89~5.20) | ＜0.000 1 | 3.14(1.81~5.46) | ＜0.000 1 | |
| 2分 | 4.99(2.40~10.37) | ＜0.000 1 | 2.61(1.06~6.42) | 0.037 | |
| 变量 | 单因素分析 | 多因素分析 | |||
| HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 性别(男/女) | 2.17(0.88~5.33) | 0.093 | |||
| BMI(≥24 kg/m2/＜24 kg/m2) | 1.64(0.78~3.44) | 0.191 | |||
| MAFLD(是/否) | 1.20(0.58~2.51) | 0.620 | |||
| Child-Pugh分级(B级/A级) | 3.54(1.52~8.25) | 0.003 | 0.99(0.28~3.52) | 0.987 | |
| 肿瘤直径(≥2 cm/＜2 cm) | 2.89(1.36~6.14) | 0.006 | 3.67(1.58~8.52) | 0.002 | |
| BCLC分期(A期/0期) | 1.10(0.33~3.63) | 0.880 | |||
| ALT(＞50 U/L/≤50 U/L) | 1.21(0.46~3.17) | 0.705 | |||
| AST(＞40 U/L/≤40 U/L) | 1.30(0.58~2.94) | 0.530 | |||
| TBil(≤20 μmol/L/＞20 μmol/L) | 2.27(1.08~4.76) | 0.030 | 1.97(0.82~4.77) | 0.132 | |
| Alb(＜35 g/L/≥35 g/L) | 3.49(1.58~7.74) | 0.002 | 1.36(0.36~5.09) | 0.649 | |
| AFP(＞400 ng/mL/≤400 ng/mL) | 1.35(0.41~4.50) | 0.621 | |||
| ALBI分级(ref: 1级) | |||||
| 2级 | 1.67(0.78~3.56) | 0.184 | 0.97(0.35~2.65) | 0.950 | |
| 3级 | 12.94(2.55~65.68) | 0.002 | 2.11(0.25~17.94) | 0.495 | |
| MELD评分(＞9分/≤9分) | 1.59(0.75~3.33) | 0.224 | |||
| N-R-L得分(ref: 0分) | |||||
| 1分 | 6.92(2.82~17.00) | ＜0.000 1 | 8.27(3.15~21.71) | ＜0.000 1 | |
| 2分 | 13.50(4.68~38.91) | ＜0.000 1 | 14.59(3.96~53.78) | ＜0.000 1 | |
| 变量 | 得分 |
| NLR | |
| ＜4.1 | 0 |
| ≥4.1 | 1 |
| RLR | |
| ＜18.3 | 0 |
| ≥18.3 | 1 |
| LMR | |
| ＜6 | 0 |
| ≥6 | 1 |
| N-R-L | |
| NLR+RLR+LMR=0 | 0 |
| NLR+RLR+LMR=1 | 1 |
| NLR+RLR+LMR=2 | 2 |
| 注：N-R-L，NLR、RLR和LMR三项评分之和。 | |
| 临床特征 | N-R-L 0分组(n=92) | N-R-L 1分组(n=29) | N-R-L 2分组(n=11) | χ2值 | P值 |
| 性别[例(%)] | 0.545 | 0.762 | |||
| 男 | 66(71.7) | 21(72.4) | 9(81.8) | ||
| 女 | 26(28.3) | 8(27.6) | 2(18.2) | ||
| 年龄[例(%)] | 0.371 | 0.831 | |||
| ＜60岁 | 48(52.2) | 17(58.6) | 6(54.5) | ||
| ≥ 60岁 | 44(47.8) | 12(41.4) | 5(45.5) | ||
| BMI[例(%)] | 2.024 | 0.363 | |||
| ＜24 kg/m2 | 42(45.7) | 9(31.0) | 5(45.5) | ||
| ≥24 kg/m2 | 50(54.3) | 20(69.0) | 6(54.5) | ||
| Child-Pugh分级[例(%)] | 10.992 | 0.001 | |||
| A级 | 81(88.0) | 26(89.7) | 4(36.4) | ||
| B级 | 11(12.0) | 3(10.3) | 7(63.6) | ||
| BCLC分期[例(%)] | 3.640 | 0.056 | |||
| 0期 | 18(19.6) | 3(10.3) | 0 | ||
| A期 | 74(80.4) | 26(89.7) | 11(100) | ||
| 肿瘤直径[例(%)] | 3.876 | 0.144 | |||
| ＜2 cm | 53(57.6) | 17(58.6) | 3(27.3) | ||
| ≥2 cm | 39(42.4) | 12(41.4) | 8(72.7) | ||
| HBV感染[例(%)] | 1.601 | 0.449 | |||
| 否 | 22(23.9) | 5(17.2) | 4(36.4) | ||
| 是 | 70(76.1) | 24(82.8) | 7(63.6) | ||
| HCV感染[例(%)] | 1.029 | 0.598 | |||
| 否 | 76(82.6) | 22(75.9) | 8(71.7) | ||
| 是 | 16(17.4) | 7(24.1) | 3(27.3) | ||
| MAFLD[例(%)] | 0.367 | 0.832 | |||
| 否 | 56(60.9) | 16(55.2) | 7(63.6) | ||
| 是 | 36(39.1) | 13(44.8) | 4(36.4) | ||
| AFP[例(%)] | 1.266 | 0.531 | |||
| ＜15 ng/mL | 59(64.1) | 21(72.4) | 6(54.5) | ||
| ≥15 ng/mL | 33(35.9) | 8(27.6) | 5(45.5) | ||
| ALBI分级[例(%)] | 2.845 | 0.092 | |||
| 1级 | 54(58.7) | 16(55.2) | 5(45.4) | ||
| 2级 | 36(39.1) | 13(44.8) | 3(27.3) | ||
| 3级 | 2(2.2) | 0 | 3(27.3) | ||
| TBil[例(%)] | 0.904 | 0.636 | |||
| ≤20 μmol/L | 55(59.8) | 16(55.2) | 5(45.5) | ||
| ＞20 μmol/L | 37(40.2) | 13(44.8) | 6(54.5) | ||
| Alb[例(%)] | 5.699 | 0.017 | |||
| ≥35 g/L | 82(89.1) | 23(79.3) | 7(63.6) | ||
| ＜35 g/L | 10(10.9) | 6(20.7) | 4(36.4) | ||
| ALT[例(%)] | 0.109 | 0.741 | |||
| ≤50 U/L | 76(82.6) | 28(96.6) | 7(63.6) | ||
| ＞50 U/L | 16(17.4) | 1(3.4) | 4(36.4) | ||
| AST[例(%)] | 1.572 | 0.456 | |||
| ≤40 U/L | 71(77.2) | 24(82.8) | 7(63.6) | ||
| ＞40 U/L | 21(22.8) | 5(17.2) | 4(36.4) | ||
| MELD评分[例(%)] | 3.022 | 0.221 | |||
| ＜9分 | 65(70.7) | 18(62.1) | 5(45.5) | ||
| ≥9分 | 27(29.3) | 11(37.9) | 6(54.5) | ||
| 注：ALBI分级，白蛋白-胆红素分级。 | |||||
| 变量 | 单因素分析 | 多因素分析 | |||
| HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 性别(男/女) | 1.97(1.14~3.40) | 0.015 | 1.55(0.87~2.76) | 0.136 | |
| BMI(≥24 kg/m2/＜24 kg/m2) | 1.22(0.77~1.92) | 0.402 | |||
| MAFLD(是/否) | 1.03(0.65~1.61) | 0.916 | |||
| Child-Pugh分级(B级/A级) | 2.58(1.50~4.45) | 0.001 | 1.28(0.56~2.91) | 0.564 | |
| 肿瘤直径(≥2 cm/＜2 cm) | 2.28(1.43~3.62) | 0.001 | 2.10(1.28~3.43) | 0.003 | |
| BCLC分期(A期/0期) | 2.06(0.89~4.75) | 0.090 | |||
| ALT(＞50 U/L/≤50 U/L) | 1.41(0.78~2.57) | 0.260 | |||
| AST(＞40 U/L/≤40 U/L) | 1.63(0.98~2.70) | 0.058 | |||
| TBil(≤20 μmol/L/＞20 μmol/L) | 1.69(1.07~2.65) | 0.024 | 1.60(0.96~2.67) | 0.074 | |
| Alb(＜35 g/L/≥35 g/L) | 2.45(1.45~4.12) | 0.001 | 1.01(0.44~2.32) | 0.974 | |
| AFP(＞400 ng/mL/≤400 ng/mL) | 0.81(0.33~2.01) | 0.650 | |||
| ALBI分级(ref: 1级) | |||||
| 2级 | 1.25(0.79~2.00) | 0.341 | 0.92(0.49~1.70) | 0.781 | |
| 3级 | 4.15(1.61~10.70) | 0.003 | 1.91(0.48~7.59) | 0.356 | |
| MELD评分(＞9分/≤9分) | 1.44(0.91~2.28) | 0.124 | |||
| N-R-L得分(ref: 0分) | |||||
| 1分 | 3.13(1.89~5.20) | ＜0.000 1 | 3.14(1.81~5.46) | ＜0.000 1 | |
| 2分 | 4.99(2.40~10.37) | ＜0.000 1 | 2.61(1.06~6.42) | 0.037 | |
| 变量 | 单因素分析 | 多因素分析 | |||
| HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 性别(男/女) | 2.17(0.88~5.33) | 0.093 | |||
| BMI(≥24 kg/m2/＜24 kg/m2) | 1.64(0.78~3.44) | 0.191 | |||
| MAFLD(是/否) | 1.20(0.58~2.51) | 0.620 | |||
| Child-Pugh分级(B级/A级) | 3.54(1.52~8.25) | 0.003 | 0.99(0.28~3.52) | 0.987 | |
| 肿瘤直径(≥2 cm/＜2 cm) | 2.89(1.36~6.14) | 0.006 | 3.67(1.58~8.52) | 0.002 | |
| BCLC分期(A期/0期) | 1.10(0.33~3.63) | 0.880 | |||
| ALT(＞50 U/L/≤50 U/L) | 1.21(0.46~3.17) | 0.705 | |||
| AST(＞40 U/L/≤40 U/L) | 1.30(0.58~2.94) | 0.530 | |||
| TBil(≤20 μmol/L/＞20 μmol/L) | 2.27(1.08~4.76) | 0.030 | 1.97(0.82~4.77) | 0.132 | |
| Alb(＜35 g/L/≥35 g/L) | 3.49(1.58~7.74) | 0.002 | 1.36(0.36~5.09) | 0.649 | |
| AFP(＞400 ng/mL/≤400 ng/mL) | 1.35(0.41~4.50) | 0.621 | |||
| ALBI分级(ref: 1级) | |||||
| 2级 | 1.67(0.78~3.56) | 0.184 | 0.97(0.35~2.65) | 0.950 | |
| 3级 | 12.94(2.55~65.68) | 0.002 | 2.11(0.25~17.94) | 0.495 | |
| MELD评分(＞9分/≤9分) | 1.59(0.75~3.33) | 0.224 | |||
| N-R-L得分(ref: 0分) | |||||
| 1分 | 6.92(2.82~17.00) | ＜0.000 1 | 8.27(3.15~21.71) | ＜0.000 1 | |
| 2分 | 13.50(4.68~38.91) | ＜0.000 1 | 14.59(3.96~53.78) | ＜0.000 1 | |
下载:
DownLoad: